Latest Headlines

1. Next Gen Diagnostics Launches NGD Infection Prevention To Provide Real-Time Transmission Detection 12/23/2025

   Next Gen Diagnostics (NGD) today announced that January 1 the Company will spin off its Infection Prevention division into an independent company, NGD Infection Prevention, focused on the implementation of real-time genomic transmission detection across U.S. hospitals.

2. Guardant Health Japan Receives Regulatory Approval Of Guardant360® CDx Liquid Biopsy As Companion Diagnostic For Imlunestrant In Metastatic Or Recurrent Breast Cancer Previously Treated With Endocrine Therapy 12/22/2025

   Guardant Health Japan Corp. today announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Guardant360® CDx on 23 October 2025 as a companion diagnostic to identify ESR1 mutations in patients with hormone receptor–positive, HER2-negative breast cancer with disease progression following endocrine therapy, for consideration of treatment with imlunestrant.

3. Marine Biological Laboratory Explores Human Memory With AI And Virtual Reality 12/22/2025

   The works of Plato state that when humans have an experience, some level of change occurs in their brain, which is powered by memory — specifically long-term memory.

4. Valar Labs Announces Strategic Partnership With PathNet Lab To Deliver AI-Driven Bladder Cancer Insights Nationwide 12/22/2025

   Valar Labs, a leader in AI-powered diagnostics for oncology, today announced a strategic partnership with PathNet Lab, one of the nation’s foremost pathology laboratories.

5. Fulgent Genetics Agrees To Acquire Bako Diagnostics And StrataDx 12/22/2025

   Fulgent Genetics, Inc. (“Fulgent”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that it has entered into a definitive agreement to acquire selected assets of Bako Diagnostics (“Bako”), a premier pathology laboratory headquartered in Alpharetta, GA and to acquire StrataDx, a premier dermatopathology laboratory located in Lexington, MA.

6. OncoInv And MaxBloch Partner To Expand Early Cancer Detection Across Central America 12/19/2025

   OncoInv, a Netherlands-based company focused on multi-cancer early detection, has signed a distribution agreement with MaxBloch Clinical Laboratories to introduce OncoSeek®, its multi-cancer early detection blood test, in El Salvador.

7. Pictor's Test Poised To Transform Hepatitis B Immunity Testing Amid CDC Guidance Shifts 12/19/2025

   With the CDC's Advisory Committee on Immunization Practices (ACIP) recommending post-vaccination antibody testing for hepatitis B, laboratories are facing new demands to assess immunity more effectively.

8. Roche Receives FDA Approval For First Diagnostic Tests To Identify HER2-Positive Metastatic Breast Cancer Patients Eligible For ENHERTU 12/17/2025

   Roche announced today that the U.S. Food and Drug Administration (FDA) has approved additional indications for its PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody and VENTANA HER2 Dual ISH DNA Probe Cocktail tests.

9. CellTivity Scientific Receives CE Registration For The Van Gogh Microscopy System, Enabling Real Time Diagnostic Sampling Support Across Europe 12/17/2025

   CellTivity Scientific, a leader in point of care disease detection, today announced that the Van Gogh Microscopy System has received CE registration, enabling clinical use and commercial distribution across the European Union.

10. Co-Diagnostics Performs Analysis Of Influenza Co-Primers® To Confirm Reactivity Against Flu A H3N2 Mutation 12/17/2025

    Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that it has performed an in silico analysis of the Co-Primers® used in its Logix Smart® ABC test* for the detection of influenza A, influenza B and COVID-19.